. . . . . . . . . . "approved"@en . . . . . . . . . . . . . "For the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism."@en . . "Frederic J. Nugent, John K. C. Yen, \"Process for preparing the combination products of triamterene and hydrochlorothiazide.\" U.S. Patent US4804540, issued July, 1987."@en . . . . "Triamt\u00E9r\u00E8ne"@en . . . . " "@en . . "Triamterenum"@en . "Rapidly absorbed, with somewhat less than 50% of the oral dose reaching the urine."@en . "55-67% (93% for the OH-TA-ester metabolite)"@en . . . . "Triamterene"@en . . . . . . . "# WellSpring Pharmaceutical Corporation. Dyrenium (triamterene) capsules prescribing information. Neptune, NJ; 2001 June. # Gilfrich HJ, Kremer G, Mohrke W, Mutschler E, Volger KD: Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. Eur J Clin Pharmacol. 1983;25(2):237-41. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/6628507"@en . "* 4.5 l/min [total plasma clearance] * 0.22 l/kg [renal plasma clearance]"@en . . . . . . "In the event of overdosage it can be theorized that electrolyte imbalance would be the major concern, with particular attention to possible hyperkalemia. Other symptoms that might be seen would be nausea and vomiting, other G.I. disturbances, and weakness. It is conceivable that some hypotension could occur. The oral LD₅₀ in mice is 380 mg/kg."@en . "Dyrenium"@en . . . . . . . . . . . . . . . "Triamteren"@en . . . "Triamterene inhibits the epithelial sodium channels on principal cells in the late distal convoluted tubule and collecting tubule, which are responsible for 1-2% of total sodium reabsorption. As sodium reabsorption is inhibited, this increases the osmolarity in the nephron lumen and decreases the osmolarity of the interstitium. Since sodium concentration is the main driving force for water reabsorption, triamterene can achieve a modest amount of diuresis by decreasing the osmotic gradient necessary for water reabsorption from lumen to interstitium. Triamterene also has a potassium-sparing effect. Normally, the process of potassium excretion is driven by the electrochemical gradient produced by sodium reabsorption. As sodium is reabsorbed, it leaves a negative potential in the lumen, while producing a positive potential in the principal cell. This potential promotes potassium excretion through apical potassium channels. By inhibiting sodium reabsorption, triamterene also inhibits potassium excretion. "@en . . . . . . . . . . . . . . . . . . . . . "396-01-0"@en . "A pteridine that is used as a mild diuretic. [PubChem]"@en . . "Teridin"@en . . . . . . . . . . . "255 minutes (188 minutes for OH-TA-ester metabolite) after IV administration."@en . . . "Triamtereno"@en . . . . . . "Humans and other mammals"@en . . . . . . "6-phenylpteridine-2,4,7-triamine"@en . . . "Triamterene"@en . . . . . . . . . . .